Source comparison
TB-500 Golfer's Elbow Mechanism: Clinical vs Preclinical Evidence
Rodent tendon injury models 40–60% increase in vascular density; 30–40% faster healing vs controls Species differences in healing rates; dosing not directly translatable to humans Mechanism is well-established; human dosing extrapolated from allometric scaling
This comparison does not assign a generated winner or score.
- Rodent tendon injury models
- 40–60% increase in vascular density; 30–40% faster healing vs controls
- Species differences in healing rates; dosing not directly translatable to humans
- Mechanism is well-established; human dosing extrapolated from allometric scaling
- Equine tendinopathy trials
- Reduced lameness scores; improved ultrasonographic tendon echogenicity
- Equine tendons heal faster than human tendons; placebo effect difficult to control
- TB-500 is widely used in veterinary sports medicine with documented outcomes
- Human case reports (off-label use)
- Subjective pain reduction in 60–70% of chronic tendinopathy cases
- No randomized controls; publication bias toward positive outcomes
- Sufficient mechanistic plausibility to justify use in research contexts
- Safety profile (Phase I human trials)
- Well-tolerated at doses up to 6mg; no serious adverse events
- Trials were short-term (8–12 weeks); long-term safety data limited
- No evidence of immunogenicity or carcinogenic risk in available studies